India, Oct. 8 -- The Government of India has issued a release:
1. Extending price protection to more cancer medicines
Government has approved a cap on the margins charged in the supply and sale of non-scheduled anti-cancer drugs.
These margins will be limited to 30% of the Maximum Retail Price (MRP). The measure is expected to reduce medicine prices by up to 70% and help cancer patients save Rs.2,500 crore annually, significantly reducing the amount they pay from their own pockets.
Essential cancer medicines included in the scheduled list are already subject to strict government-set ceiling prices. The new decision extends price protection to non-scheduled cancer medicines, which are outside that list, by limiting the margins added bef...